A comprehensive view of vaccination/immunization. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Pfizer responds to accusations about its alleged manipulation of Covid virus to create new vaccines, stating it has not conducted gain-of-function or targeted evolution research; company acknowledges it has conducted research on original Sars-CoV-2 virus
Published: January 31, 2023 by CE Noticias Financieras (Latin America)
Pfizer first pharmaceutical company with over US$100.0B in sales, reporting sales of US$100.33B in 2022; profits increased 43% year-over-year to US$31.4B, more than triple the profits in 2020
Published: January 31, 2023 by CE Noticias Financieras (Latin America)
Pfizer expects COVID-19 vaccine and Paxlovid pill revenues will fall 60% in 2023 to US$21.5B; Pfizer estimated COVID-19 vaccine demand will drop 29% to about 65 million doses this year due to end of government funding for the shot
Published: January 31, 2023 by Forbes
Moderna expands partnership with Swiss biopharma CDMO Lonza to increase production of COVID-19 vaccine drug substances; Lonza to add new manufacturing line at Geleen, Netherlands, plant with capacity to add up 300 million doses per year
Published: January 30, 2023 by Chemical Weekly (CBNB Abstracts)
Moderna granted FDA breakthrough therapy designation for its mRNA-1345 investigational RSV vaccine candidate in adults aged 60 years and older; in US, about 60,000-120,000 older adults are hospitalized with RSV every year
Published: January 30, 2023 by Moderna Inc.

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count